• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Cetuximab plus chemoradiotherapy for anal carcinoma in immunocompetent patients does not change existing therapy standards : Results from the prospective, multicenter E3205 trial].

作者信息

Nieder Carsten

机构信息

Dept. of Oncology and Palliative Medicine, Nordland Hospital Trust, Prinsensgate 164, P.O. Box 1480, 8092, Bodø, Norwegen.

出版信息

Strahlenther Onkol. 2017 Jun;193(6):508-509. doi: 10.1007/s00066-017-1133-x.

DOI:10.1007/s00066-017-1133-x
PMID:28409247
Abstract
摘要

相似文献

1
[Cetuximab plus chemoradiotherapy for anal carcinoma in immunocompetent patients does not change existing therapy standards : Results from the prospective, multicenter E3205 trial].[西妥昔单抗联合放化疗用于免疫功能正常的肛管癌患者并未改变现有治疗标准：前瞻性多中心E3205试验结果]
Strahlenther Onkol. 2017 Jun;193(6):508-509. doi: 10.1007/s00066-017-1133-x.
2
Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.西妥昔单抗联合伊立替康治疗难治性肛管鳞状细胞癌患者的临床活性证据：病例报告
Dis Colon Rectum. 2007 Mar;50(3):395-8. doi: 10.1007/s10350-006-0786-9.
3
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.局部晚期肛门癌患者中西妥昔单抗联合氟尿嘧啶、丝裂霉素 C 和放疗的 I 期研究。
Eur J Cancer. 2015 Dec;51(18):2740-6. doi: 10.1016/j.ejca.2015.08.029. Epub 2015 Nov 18.
4
Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.西妥昔单抗联合传统放化疗治疗局部晚期肛管癌患者的缓解率较低：UNICANCER ACCORD 16 II期试验的长期结果
Radiother Oncol. 2015 Mar;114(3):415-6. doi: 10.1016/j.radonc.2015.02.008. Epub 2015 Mar 11.
5
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.局部晚期肛管癌患者中西妥昔单抗联合氟尿嘧啶、顺铂和放疗的 1 期研究。
Cancer. 2013 Aug 15;119(16):2973-80. doi: 10.1002/cncr.28045. Epub 2013 May 14.
6
EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.表皮生长因子受体抑制剂治疗晚期肛管鳞状细胞癌患者：单机构经验
Oncology. 2017;92(4):190-196. doi: 10.1159/000452766. Epub 2017 Feb 3.
7
Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck.使用西妥昔单抗或基于顺铂的化疗对头颈部复发性鳞状细胞癌进行再照射。
Strahlenther Onkol. 2015 Aug;191(8):656-64. doi: 10.1007/s00066-015-0854-y. Epub 2015 May 25.
8
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).西妥昔单抗联合放化疗在可切除局部进展期食管癌患者术前治疗中的前瞻性多中心 Ib/II 期研究（SAKK75/06）。
J Clin Oncol. 2011 Feb 20;29(6):626-31. doi: 10.1200/JCO.2010.31.9715. Epub 2011 Jan 4.
9
Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer.诱导化疗和放疗联合西妥昔单抗治疗头颈部癌症的疗效和可行性。
Anticancer Res. 2012 Jan;32(1):195-9.
10
Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.多西他赛、顺铂和西妥昔单抗同步放化疗治疗局部晚期头颈部鳞状细胞癌的II期试验
Cancer Chemother Pharmacol. 2016 Jun;77(6):1315-9. doi: 10.1007/s00280-016-3052-4. Epub 2016 May 6.

本文引用的文献

1
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.肛管鳞状细胞癌放化疗后评估完全临床缓解的最佳时间（ACT II）：一项随机对照3期试验的事后分析
Lancet Oncol. 2017 Mar;18(3):347-356. doi: 10.1016/S1470-2045(17)30071-2. Epub 2017 Feb 11.
2
Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.表皮生长因子受体与Ki67共表达对接受放化疗的肛管癌患者临床结局的意义：NRG肿瘤学RTOG 9811分析
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):554-562. doi: 10.1016/j.ijrobp.2016.11.021. Epub 2016 Nov 23.
3
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).西妥昔单抗联合放化疗用于免疫功能正常的肛管癌患者：一项东部肿瘤协作组-美国放射学会影像网络癌症研究组的II期试验（E3205）
J Clin Oncol. 2017 Mar;35(7):718-726. doi: 10.1200/JCO.2016.69.1667. Epub 2017 Jan 9.
4
Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.采用同步整合加量调强放疗治疗肛管癌：悉尼两家机构的3年结果
Clin Oncol (R Coll Radiol). 2015 Dec;27(12):700-7. doi: 10.1016/j.clon.2015.08.006. Epub 2015 Sep 14.
5
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.丝裂霉素或顺铂放化疗联合或不联合维持化疗治疗肛门鳞癌（ACT II）：一项随机、3 期、开放性、2×2 析因试验。
Lancet Oncol. 2013 May;14(6):516-24. doi: 10.1016/S1470-2045(13)70086-X. Epub 2013 Apr 9.
6
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.美国胃肠肿瘤学组 RTOG 98-11 期临床试验的长期随访：同步放化疗中含氟尿嘧啶/丝裂霉素与氟尿嘧啶/顺铂治疗肛门癌的生存、复发和结肠造口失败情况。
J Clin Oncol. 2012 Dec 10;30(35):4344-51. doi: 10.1200/JCO.2012.43.8085. Epub 2012 Nov 13.